Proteomics analysis of serum from thymoma patients

Li, Jiaduo; Qi, Guoyan; Liu, Yaling

doi:10.1038/s41598-023-32339-4

Cited by 6 publications

(1 citation statement)

References 49 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proteome of THs is still a relatively unexplored area of research. A number of publications have analyzed the thymoma proteome in an unbiased manner using either tissue lysates [ 4 , 110 , 112 , 113 , 114 , 115 ] or serum [ 116 , 117 , 118 , 119 ].…”

Section: Proteomics and Altered Tyrosine Kinase Signalingmentioning

confidence: 99%

Non-Mutational Key Features in the Biology of Thymomas

Küffer,

Müller,

Marx

et al. 2024

Cancers

View full text Add to dashboard Cite

Thymomas (THs) are a unique group of heterogeneous tumors of the thymic epithelium. In particular, the subtypes B2 and B3 tend to be aggressive and metastatic. Radical tumor resection remains the only curative option for localized tumors, while more advanced THs require multimodal treatment. Deep sequencing analyses have failed to identify known oncogenic driver mutations in TH, with the notable exception of the GTF2I mutation, which occurs predominantly in type A and AB THs. However, there are multiple alternative non-mutational mechanisms (e.g., perturbed thymic developmental programs, metabolism, non-coding RNA networks) that control cellular behavior and tumorigenesis through the deregulation of critical molecular pathways. Here, we attempted to show how the results of studies investigating such alternative mechanisms could be integrated into a current model of TH biology. This model could be used to focus ongoing research and therapeutic strategies.

show abstract

Section: Proteomics and Altered Tyrosine Kinase Signalingmentioning

confidence: 99%

Non-Mutational Key Features in the Biology of Thymomas

Küffer,

Müller,

Marx

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma

Xu,

Li,

et al. 2024

Biol Direct

View full text Add to dashboard Cite

Construction of five disulfidptosis-related lncRNA signature for predicting prognosis and immune activity in kidney renal clear cell carcinoma

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Kidney renal clear cell carcinoma (KIRC) is a highly aggressive cancer. Disulfidptosis is a newly discovered mechanism of programmed cell death. However, the role of disulfidptosis-related lncRNAs (DRlncRNAs) in KIRC remains unknown. This study aimed to develop a prognostic model of DRlncRNAs and explore their prognostic value in KIRC. RNA-seq and relevant clinical data were obtained from The Cancer Genome Atlas (TCGA) database. Univariate Cox regression, lasso algorithm and multivariate Cox regression analysis identified DRlncRNAs and established a prognostic model. Multiple methods to assess the reliability of the model. In addition, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, somatic mutation analysis, and drug prediction were performed on the model. qRT-PCR has identified the intracellular expression of DRlncRNAs. We constructed a prognostic model with five DRlncRNAs and proved that the model was a good predictor of survival and prognosis of KIRC patients. GSEA indicated that DRlncRNAs were associated with apoptosis and immune-related pathways. Immune correlation analysis suggested that low-risk patients had better immunotherapeutic outcomes. Besides, somatic mutation analysis revealed that low-risk patients had a lower somatic mutation rate and TMB score and better prognostic. Drug prediction showed that axitinib, ibrutinib, osimertinib, and ruxolitinib were more effective in the low-risk patients; Crizotinib, lapatinib, linsitinib, and nilotinib were more effective in the high-risk patients. Finally, qRT-PCR confirmed the expression of DRlncRNAs in normal kidney cells and KIRC cell lines. In summary, we constructed a risk model and provided a new direction for diagnosing and treating KIRC.

show abstract

Proteomics analysis of serum from thymoma patients

Cited by 6 publications

References 49 publications

Non-Mutational Key Features in the Biology of Thymomas

Non-Mutational Key Features in the Biology of Thymomas

Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma

Construction of five disulfidptosis-related lncRNA signature for predicting prognosis and immune activity in kidney renal clear cell carcinoma

Contact Info

Product

Resources

About